Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747929 · ClinicalTrials.gov registry record · Phase 2
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
A Phase 2 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 724
- Enrollment target
NCT00747929 is a Phase 2 study that has completed, run by Shionogi. The registered enrollment target is 724 participants.
The verdict
NCT00747929, a Phase 2 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 724 participants
- Enrollment target
Study Summary
1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects 2. To evaluate the safety and tolerability of S-2367 during 54 weeks of drug exposure 3. To evaluate the steady-state/trough pharmacokinetics of S-2367
Interventions
- DRUG S-2367 Placebo
- OTHER Reduced Calorie Diet
- DRUG S-2367 800 mg
- DRUG S-2367 1600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747929
The ClinicalTrials.gov registry entry for NCT00747929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 724 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which S-2367 Placebo is the first listed.
NCT00747929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00747929 about?
NCT00747929 is a clinical study titled "Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet". 1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects 2. To evaluate the safety and tolerability of S-2367 during 54 ...
What is the current status of trial NCT00747929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 724 participants. The study started on 2007-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00747929?
The interventions under investigation include: S-2367 Placebo (DRUG), Reduced Calorie Diet (OTHER), S-2367 800 mg (DRUG), S-2367 1600 mg (DRUG).
Who is sponsoring clinical trial NCT00747929?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.